Pitch

Community

Team

Portfolio

News

Discover how our portfolio companies are accelerating

equitable innovation and closing gaps in health outcomes for

underserved communities.

News

Discover how our portfolio companies are accelerating

equitable innovation and closing gaps in health outcomes for

underserved communities.

News

Discover how our portfolio companies are accelerating

equitable innovation and closing gaps in health outcomes for

underserved communities.

Latest: 2Flo Ventures Health Equity Pitch Competition

April 1, 2024

Latest: 2Flo Ventures Health Equity Pitch Competition

April 1, 2024

Latest: 2Flo Ventures Health Equity Pitch Competition

April 1, 2024

Recent Posts

Women In Bio - Brilliance of Diversity sponsored by 2Flo Venutres and Diversity Health NetWoRx

February 28, 2024

Women In Bio - Brilliance of Diversity sponsored by 2Flo Venutres and Diversity Health NetWoRx

February 28, 2024

Women In Bio - Brilliance of Diversity sponsored by 2Flo Venutres and Diversity Health NetWoRx

February 28, 2024

SF JPM Reception by 2Flo Ventures and WOCIP

January 12, 2024

SF JPM Reception by 2Flo Ventures and WOCIP

January 12, 2024

SF JPM Reception by 2Flo Ventures and WOCIP

January 12, 2024

Vivacelle Bio Featured in The Lancet Journal

January 28, 2024

Vivacelle Bio Featured in The Lancet Journal

January 28, 2024

Vivacelle Bio Featured in The Lancet Journal

January 28, 2024

2Flo Health Equity Investing Symposium Connects Chicago Investors and Entrepreneurs

September 14, 2023

2Flo Health Equity Investing Symposium Connects Chicago Investors and Entrepreneurs

September 14, 2023

2Flo Health Equity Investing Symposium Connects Chicago Investors and Entrepreneurs

September 14, 2023

Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis

December 15, 2022

Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis

December 15, 2022

Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis

December 15, 2022

Industry Voices—Why now is the time for inclusive health investment

October 25, 2022

Industry Voices—Why now is the time for inclusive health investment

October 25, 2022

Industry Voices—Why now is the time for inclusive health investment

October 25, 2022

4D Healthware COO, Angela Littrell, attends Health Conference

October 4, 2022

4D Healthware COO, Angela Littrell, attends Health Conference

October 4, 2022

4D Healthware COO, Angela Littrell, attends Health Conference

October 4, 2022

Dr. Modestus Obochi joins the 2Flo Ventures Advisory Committee and the Temprian Therapeutics Board of Directors

September 12, 2022

Dr. Modestus Obochi joins the 2Flo Ventures Advisory Committee and the Temprian Therapeutics Board of Directors

September 12, 2022

Dr. Modestus Obochi joins the 2Flo Ventures Advisory Committee and the Temprian Therapeutics Board of Directors

September 12, 2022

CancerIQ Closes a $14M Series B Funding to Improve Access to Innovations in Cancer Early Detection and Prevention

September 12, 2022

CancerIQ Closes a $14M Series B Funding to Improve Access to Innovations in Cancer Early Detection and Prevention

September 12, 2022

CancerIQ Closes a $14M Series B Funding to Improve Access to Innovations in Cancer Early Detection and Prevention

September 12, 2022

2Flo Ventures Portfolio Companies Focused on Health Equity at BIO International Convention

July 11, 2022

2Flo Ventures Portfolio Companies Focused on Health Equity at BIO International Convention

July 11, 2022

2Flo Ventures Portfolio Companies Focused on Health Equity at BIO International Convention

July 11, 2022

Akan Biosciences Announces FDA Acceptance of IND Application for StroMel™ in Osteoarthritis of Knee

February 16, 2021

Akan Biosciences Announces FDA Acceptance of IND Application for StroMel™ in Osteoarthritis of Knee

February 16, 2021

Akan Biosciences Announces FDA Acceptance of IND Application for StroMel™ in Osteoarthritis of Knee

February 16, 2021

Vivacelle Bio Receives $5.3 Million Award from the US Navy for a Clinical Trial of VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens

November 24, 2020

Vivacelle Bio Receives $5.3 Million Award from the US Navy for a Clinical Trial of VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens

November 24, 2020

Vivacelle Bio Receives $5.3 Million Award from the US Navy for a Clinical Trial of VBI-S for Treatment of Hypovolemia of Septic Shock Due to COVID or other Pathogens

November 24, 2020

CancerIQ raises $4.8M Series A funding round for cancer precision health technology

August 13, 2020

CancerIQ raises $4.8M Series A funding round for cancer precision health technology

August 13, 2020

CancerIQ raises $4.8M Series A funding round for cancer precision health technology

August 13, 2020

Nature selects Temprian Therapeutics as a finalist for their Spinoff Prize 2020, which celebrates early stage university spinoff companies.

July 2, 2020

Nature selects Temprian Therapeutics as a finalist for their Spinoff Prize 2020, which celebrates early stage university spinoff companies.

July 2, 2020

Nature selects Temprian Therapeutics as a finalist for their Spinoff Prize 2020, which celebrates early stage university spinoff companies.

July 2, 2020

Vivacelle Bio Announces Compassionate Use for COVID-19 Patients with Its Sepsis Treatment, VBI-S

April 21, 2020

Vivacelle Bio Announces Compassionate Use for COVID-19 Patients with Its Sepsis Treatment, VBI-S

April 21, 2020

Vivacelle Bio Announces Compassionate Use for COVID-19 Patients with Its Sepsis Treatment, VBI-S

April 21, 2020

4D Healthware’s Enhanced Telehealth Solution Reduces Covid-19 Patient Visits to the Doctor’s Office

March 25, 2020

4D Healthware’s Enhanced Telehealth Solution Reduces Covid-19 Patient Visits to the Doctor’s Office

March 25, 2020

4D Healthware’s Enhanced Telehealth Solution Reduces Covid-19 Patient Visits to the Doctor’s Office

March 25, 2020